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Background: Group B Streptococcus (GBS) is a major cause of mortality and mor-
bidity in infants and is associated with transmission from a colonized mother at birth 
and via infected breastmilk. Although maternal/infant colonization with GBS is common, 
the majority of infants exposed to GBS remain unaffected. The association between 
breastmilk immune factors and infant colonization and disease prevention has not been 
elucidated.
Objectives: We have investigated the association between SIgA and cytokines in 
breastmilk and infant GBS colonization and clearance.
Methods: Mother/infant GBS colonization was determined in a prospective cohort of 
750 Gambian mother/infant pairs followed to day 89 of life. Anti-GBS secretory IgA 
bound to the surface of whole bacteria was assessed by flow cytometry and a panel 
of 12 cytokines quantified by mesoscale discovery in colostrum, breastmilk and serum.
results: Compared with infants receiving low anti-GBS SIgA in colostrum, infants 
receiving high anti-GBS SIgA were at decreased risk of GBS colonization for serotypes 
III and V. Infants colonized at day 6 were twice as likely to receive colostrum with high 
TGF-β1, TNFα, IL10, and IL-6 compared to uncolonized infants. Infants receiving high 
colostral TGF-β1, TNFα, and IL-6 had two-fold enhanced GBS clearance between birth 
and day 89.
conclusion: Our results suggest that the infant GBS colonization risk diminishes with 
increasing anti-GBS SIgA antibody in breastmilk and that key maternally derived cyto-
kines might contribute to protection against infant colonization. These findings might be 
leveraged to develop interventions including maternal vaccination that may reduce infant 
GBS colonization.
Keywords: breast milk, antibody, cytokines, neonatal immunity, microbiome, group B Streptococcus
Abbreviations: GBS, group B Streptococcus; SIgA, secretory Ig A; FI-C, fluorescence intensity; STGG, skim-milk tryptone 
glucose glycerol; ST, serotype; PBS, phosphate buffered saline; BSA, bovine serum albumin.
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inTrODUcTiOn
Given the limited ability of newborns to respond efficiently to 
infectious agents, including at the mucosal surface, there is 
increasing interest in identifying maternal factors that may 
influence protection from infections in the early months of 
life. Neonatal immunity can be influenced by maternal factors 
through transfer of specific antibody across the placenta as well 
as via breastmilk (1). Several studies have shown that breastfed 
infants are better protected from infections of the gastrointestinal 
and respiratory tracts compared to formula-fed infants (2–4). 
The neonatal gut immune system is constantly modulated by 
colostrum and breastmilk, promoting the growth of certain bac-
teria over others and thereby influencing the neonatal immune 
response (1). Evidence now supports a connection between the 
mother’s gastrointestinal tract and the mammary glands via an 
“entero-mammary circulation,” which may play a role in immune 
priming (5).
One of the most important factors in breastmilk is secretory 
IgA (SIgA). SIgA mediates protection via binding to mucosal 
pathogens as well as neutralization of toxins and virulence 
factors. SIgA antibodies can prevent bacterial adhesion by bind-
ing to pili and other adhesins found on the surface of group B 
Streptococcus (GBS) (6, 7).
It is also established that cytokines in breastmilk vary accord-
ing to maternal exposure to bacteria (8). TGF-β, IL-6, and IL-10 
in breastmilk may enable the development and differentiation 
of neonatal cells that produce IgA (9) and are involved in the 
maturation of the neonatal gut immune system (10). It has also 
been shown that TGF-β1 and TGF-β2 in colostrum are positively 
correlated with infant IgA in neonatal serum (11, 12).
Little is known about the impact of cytokines and SIgA in 
breastmilk on bacterial colonization and clearance in general and 
in relation to GBS in particular. We tested the hypothesis that 
SIgA and breastmilk cytokines could influence infant coloniza-
tion and clearance over the first three months of life in a cohort 
of Gambian infants.
MaTerials anD MeThODs
Samples were collected in an urban clinic in The Gambia, West 
Africa as part of a wider study of GBS infection previously reported 
(13). Ethical approval was given by the Gambia Government/
MRC Joint Ethics committee (reference SCC 1350v4).
sample collection
Sample collection and microbiology have been previously 
described (13). Briefly, 750 pregnant women between the ages 
of 18 and 40 years who had a low-risk, singleton pregnancy were 
recruited after giving informed consent. The study excluded 
very preterm (<32  weeks gestation) or very low birth weight 
(<2.0 kg) infants. Colostrum was collected within 12 h of birth 
and breastmilk was collected at day 6 and 60–89 days of life. After 
washing their hands, mothers wiped each breast with an alcohol 
wipe beforehand expressing 2–3 mL of colostrum and 4–5 mL of 
breastmilk. Milk samples were stored on cold packs at 4°C and 
transported to the laboratory within 6 h of collection. The lipid 
and whey layers were separated by centrifugation at 3,200 rpm for 
30 min. The solid lipid layer was removed using a sterile scalpel 
and the whey stored separately in 1 mL aliquots at −70°C.
Midwives or field nurses collected rectovaginal swabs 
(Copan, UK) after cleaning of the perineum when women pre-
sented to the hospital in labor. Infant nasopharyngeal (calcium 
alginate swabs, Sterilin, UK) and rectal swabs (Copan, UK) 
were taken at 4 h of life, on day 6 and at day 60–89. Swabs were 
stored in 5 mL skim-milk tryptone glucose glycerol (STGG) on 
cold packs at 4°C and transported to the laboratory within 6 h of 
collection. The swab in STGG was vortexed briefly before being 
stored at −70°C (13).
Microbiological and Molecular 
Quantification of gBs colonization
The protocol was adapted from the Public Health England (PHE) 
protocol for the pre-incubation of swabs in enrichment broth 
before plating on solid media to enhance the yield of GBS (14). 
Swab samples were processed within 7  days of collection in 
batches of 100. Swabs in STGG were thawed on wet ice and trans-
ported to the microbiology laboratory. Samples were vortexed 
for 10–20  s and 100  µL of vortexed specimen was transferred 
to 2.5 mL Todd Hewitt Broth for 24 h pre-culture at 37°C in an 
atmosphere of 5% CO2. A Colombia Agar plate was divided into 
four segments, and 10 µL of neat suspension and each of three 
1:10 dilutions were dispensed into each of the four quadrants 
and incubated overnight at 37°C in 5% CO2. From the primary 
plate, presumptive beta hemolytic Streptococcus colonies were 
streaked onto a blood agar plate and reincubated at 37°C in 5% 
CO2 for 24 h. Beta hemolytic streptococci appeared colorless or 
gray, about 2  mm in diameter with or without a surrounding 
zone of beta-hemolysis. Streptex® (Oxoid, UK) was used in the 
qualitative identification of GBS. Samples were serotyped using 
PCR as previously described (13).
All infants were exclusively breastfed and all samples were 
collected before feeds to ensure samples were not contaminated 
with oral bacteria.
cytokine Quantification
The concentrations of cytokines IL-1β, IL-2, IL-4, IL-6, IL-10, 
IL-12, IL-13, IFN-γ, TNFα, and TGF-β1 were determined 
in the cord serum, colostrum, and breastmilk of a subset of 
100 randomly selected Gambian mothers and serum from 
their infants at day 60–90, using electroluminescence via the 
Meso-Scale Discovery system and the Proinflammatory Panel 
1 (human) MSD Multi-Spot Kit (MSD, Rockville, MD, USA). 
First, multi-analyte calibrator solution containing recombinant 
human cytokines at known concentrations, which have been 
expressed in E. coli or Sf21 insect cells, was reconstituted using 
the diluent provided. The calibrator was diluted fourfold six 
times to generate a series of seven reference calibrators to which 
unknown serum/breastmilk samples were compared. All serum/
colostrum/breastmilk samples were diluted two-fold in the same 
diluent before addition to the plate. 50 µl of the diluted serum or 
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breastmilk and calibrators were added to each well. Plates were 
incubated at room temperature for 2 h and then washed three 
times with phosphate-buffered saline (PBS) containing 0.05% 
Tween-20. 25 µl of a solution containing detection antibody to 
each cytokine was added to each well. Plates were then incubated 
for a further 2  h at room temperature. After the incubation, 
plates were washed and 150  µl read buffer added. Plates were 
then read using the MESO QuickPlex SQ 120 MSD instru-
ment. Samples below the limit of quantification were allocated 
a value for each cytokine of half the lower limit of detection 
as per manufacturer’s instructions. Details of each lower limit 
of quantification and the associated allocations for analysis are 
found in Table S2 in Supplementary Material. The coefficient of 
variance (CoV) for the assay was 25%.
siga Binding to gBs Bacteria
The assay was adapted from a serological assay described by 
Le Doare et al. (15) which quantified IgG binding to GBS bac-
teria using serum samples. GBS isolates used in this study were 
H092040676 (ST Ia), H092120162 (ST III), and H091780506 
(ST V), which were kindly provided by Professor Androulla 
Efstratiou, PHE, Colindale. 5  µl of the breastmilk sample was 
added to a 96 well micro-titer plate and incubated with 195 µl of 
killed GBS of STs Ia, III, and V diluted to OD 0.05 (at 600 nm) 
in PBS with 2% bovine serum albumin (BSA) for 30 min at 25°C 
while shaking at 900 rpm. After centrifuging at 3,060 g for 5 min, 
excess fluid was removed. The pellet was washed with 200 µl of 
PBS with 2% BSA before centrifuging. The pellets were then re-
suspended in rabbit anti-human SIgA polyclonal FITC antibody 
(BIOSS, Woburn USA) diluted to 1:100 in PBS with 2% BSA. This 
was incubated at 4°C for 20 min. After centrifugation, the pellet 
was washed twice. The final pellet was re-suspended in PBS with 
1% formaldehyde to kill any sample bacteria in the breastmilk 
before SIgA binding was analyzed using a Beckman Coulter Cyan 
flow cytometer with attached Cytek 96 well plate loader (High 
Wycombe, UK) calibrated with Ultra rainbow beads (San Diego, 
CA, USA). A secondary gate was set to 10% of the histogram of 
the bacteria and conjugate wells providing a percentage gated 
value for each of the samples. The percentage gated and the mean 
fluorescence for that population were multiplied together to give 
a fluorescence index (FI). The FI of the conjugate control was 
subtracted from each sample’s mean Fl to remove background, 
non-specific binding. This is referred to as florescence intensity 
(FI-C) (see Figure S1 in Supplementary Material). For the meas-
urement of SIgA deposition, raw data were plotted and used in 
the analysis. Where no antibody deposition was detected, these 
data were given a value of ND and excluded from analysis; all 
samples were run in duplicate and samples were accepted if the 
standard error was < 5%. Over the course of the study, the mean 
SD of FI for zymozan controls was 8,831 (CoV, 31.6%).
statistical analysis and sample size 
calculation
To ensure that the study avoided bias, we followed the statistical 
design of experiments for cluster analysis method (16). Based 
on estimates from the original study in The Gambia [21% 
infants colonized (158/750); 6.5% prevalence of the lowest 
serotype GBS STIa] (13) a sample size of 750 women would 
be required to give at least ten women/5 infants colonized 
with GBS STIa. Five infants for each GBS ST would give 80% 
power to detect a correlation of 70% or greater between GBS 
ST-specific antibody and colonization.
STATA version 12 (StataCorp 2013, California, CA, USA) and 
GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, 
CA, USA) were used for statistical analysis. Additional statistical 
support was provided by Fiona Warburton (PHE) who verified 
all statistical analysis.
Potential differences between cytokines in colostrum and 
breastmilk were calculated using the Mann–Whitney U Tests 
or Wilcoxon Rank sum tests. Radar plots were generated to 
demonstrate the distribution of cytokines between colonization 
groups. Odds ratios, adjusted odds ratios, and analysis of variance 
(ANOVA) were calculated to compare groups. Potential differ-
ences in antibody concentrations between colonized and non-
colonized mothers and infants were evaluated by Student’s t-test 
after log transformation of data. Three groups were compared 
(mother colonized/infant non-colonized; mother colonized/
infant colonized; and neither mother nor infant colonized) using 
ANOVA following log-transformation of data. Comparison of 
log-transformed serum FI-C values at day 6 and 60–89 days was 
performed using a paired t-test. Linear regression was calculated 
from log transformed data to determine IgG in serum and IgA 
in breastmilk.
Definitions
Maternal colonization was defined as the identification of a 
GBS-positive rectovaginal swab at time of delivery. Infant 
colonization was defined as the identification of a GBS-positive 
nasopharyngeal and/or rectal swabs at 4 h (birth), day 6 (early 
colonization), or day 60–89. We identified infants colonized 
both at birth and day 6 as the baseline colonization point to 
ensure we captured only true colonization episodes. Infant 
acquisition of colonization was defined as a positive naso-
pharyngeal and/or rectal swab at day 6 and/or day 60–89 when 
the associated swab from the previous visit was negative, and 
loss was defined as a negative nasopharyngeal and/or rectal 
swab when the previous swab was GBS-positive. Persistently 
colonized infants were defined as infants where nasopharyn-
geal and rectal swabs at birth, day 6, and day 60–89 were all 
GBS positive.
resUlTs
The maternal GBS colonization rate was 32% (n = 237), with 21% 
of infants colonized at birth (n = 158), 20% colonized at day 6 
(n = 152), and 7% of infants colonized on day 60–89 (n = 50) 
(13). 680 colostrum and 750 breastmilk samples were available 
for analysis.
We examined the presence of GBS in breastmilk from all 750 
women and found 10 to be GBS colonized in breastmilk.
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relationship between siga in Breastmilk 
and Maternal gBs-colonization status
Overall, 324/680 (47.6%) colostrum samples had detectable 
SIgA against any GBS ST. There was no significant difference in 
SIgA concentration between non-colonized mothers and those 
colonized with STs Ia [GBS + mother FI-C 1300 (1,000–1765) 
GBS-mother 1500 (1000–1886) p = 0.3], III [GBS + 1713 (1,545–
4,837), GBS-1995 (1,798–2,223) (p =  0.3)], or V [GBS +  2089 
(1,883–5,896) GBS-2691 (2,426–2,985) (p = 0.8)].
There was no difference in IgA antibody concentrations 
found between those women colonized in breastmilk and those 
uncolonized.
relationship between siga in colostrum 
and Maternal/infant colonization on Day 6
152 infants [152/680 (22.4%)] were colonized both at birth and 
on day 6 of life. Colonized infants born to colonized mothers 
received colostrum with lower SIgA binding to GBS than any 
other colonization group. Non-colonized infants born to colo-
nized mothers received colostrum with significantly higher SIgA 
than colonized mother/infant pairs for STIII and STV, when 
adjusted for maternal age, maternal weight, maternal anemia, and 
gestation (p < 0.0001) (Figure 1).
siga in colostrum is associated  
with absence of infant colonization  
at Days 60–89
Compared to infants who remained colonized on day 60–89, 
non-colonized infants received higher SIgA concentrations 
against STV in colostrum (p < 0.001). There were no infants who 
remained colonized with STIa and only three infants remained 
colonized with STIII. Infants who cleared colonization between 
birth and day 6 also received colostrum with higher concentra-
tions of SIgA than those infants who remained colonized for STV 
(Figure 1). In addition, non-colonized infants at 60–89 days were 
more likely to have higher antibody concentrations in cord blood 
and in infant serum (p < 0.001). There was a positive correlation 
between SIgA in colostrum and complement-mediated antibody 
deposition in cord blood and in infant serum found in the main 
study (R = 0.67, p < 0.0001) (17).
cytokines in colostrum, Breastmilk,  
and infant serum
Significantly higher concentrations of TNFα, IFNγ, IL-1β, IL-2, 
IL-4, IL-6, IL-10, IL-12, IL-13 (p < 0.0001 for all) were found in 
colostrum in comparison with breastmilk, cord blood, or infant 
serum at days 60–89. Breastmilk had lower concentrations of 
TNFα, IL-1β, IL-6, and IL-13 (p <  0.0001) than infant serum. 
Low levels of IL-2, IL-4, and IL-12 were found in all samples. 
Associations between cytokines in colostrum, breastmilk, cord 
blood, and infant serum are highlighted in Figure 2.
relationship between cytokines in 
colostrum and early infant colonization
Infants who were still colonized on day 6 of life were more 
likely to receive colostrum with high concentrations of TGF-β1 
[OR 1.45 (1.1–1.9), p =  0.02], IL-10 [2.8 (1.1–7.5), p =  0.05], 
TNFα [2.4 (1.1–5.0), p = 0.02], and IL-6 [2.4 (1.2–5.0), p = 0.02] 
than non-colonized infants (Figure  3). Multivariate logistical 
regression adjusted for other cytokines showed that colonized 
infants were more likely to receive colostrum with high concen-
trations of TGF-β, IL-10, TNFα, and IL-6 than non-colonized 
infants [AOR 3.2 (1.8–9.2), p = 0.03]. There was no association 
with any other cytokine at day 6.
relationship between cytokines  
in colostrum and acquisition and 
clearance of infant colonization  
between Birth and Days 60–89
Median concentrations of ten cytokines in colostrum were com-
pared for all four mother/infant groups. As shown in Figure 4, 
infants who cleared colonization between birth and days 60–89 
(n = 27) received colostrum with higher concentrations of TNFα, 
IL-6, and TGF-β1 (p = 0.01) than infants who acquired coloniza-
tion between birth and day 60–89 [AOR 2.4 (1.2–5.0), p = 0.02]. 
Infants who were persistently colonized (n = 7) received higher 
concentrations of IFN-γ in colostrum than infants who acquired 
colonization (n = 28) [AOR 5.1 (2.4–11.0), p < 0.001]. There was 
no association between other cytokines in breastmilk and infant 
colonization at day 60–89 (Figure 4).
DiscUssiOn
The results from our large cohort of mother/infant pairs show for 
the first time that SIgA and key immunomodulatory cytokines 
TNFα, IL-6, IL-10, and TGF-β in colostrum may be associated 
with infant GBS colonization, acquisition, and clearance up to 
3 months of life.
Few studies have focused on the relationship between SIgA 
in breast milk and infant colonization with potential pathogens. 
Given that infant GBS colonization is the pre-requisite for dis-
ease, investigating factors that can reduce infant colonization 
is important, as manipulation of such factors could reduce the 
risk of invasive disease. Our data, obtained using an assay that 
measures SIgA that binds to whole GBS bacteria of STs Ia, III, 
and V, demonstrate that compared to all other mother/infant 
groups, the lowest anti-GBS SIgA levels were found in colonized 
mother/infant pairs. We also show that infants receiving the 
lowest concentration of anti-GBS SIgA in breastmilk were less 
likely to clear GBS colonization. Several studies have investigated 
anti-GBS antibody levels in breastmilk. Lagergard et  al. (1992) 
identified IgA antibodies to CPS type III GBS in 63% of a cohort 
of 70 Swedish women (18), while Weisman and Dobson (1991) 
determined anti-STIa, II or III CPS IgG in a cohort of 46 USA 
women and found levels at approximately 10% of those in mater-
nal serum (19). The most recent study of SIgA was conducted 
by Edwards et al. (2004). The study investigated IgG and IgA in 
breast milk to GBS ST III CPS in 9 colonized and 9 non-colonized 
women with antibody titers less than or equal to 1 µg/mL and 
those greater than 1 µg/mL and also found that detectable levels 
of anti-STIII SIgA in breastmilk correlated with high levels in 
maternal serum (20).
FigUre 1 | Relationship between SIgA in colostrum and maternal and infant colonization group for STIII and STV. Mean and SD of log transformed florescence 
intensity (FI-C) of SIgA deposition onto the surface of whole group B Streptococcus (GBS) bacteria STIII and STV at day 6 (a,c) and clearance of colonization 
between day 6 and day 60–89 (B,D). STIII (n = 3 persistent, n = 12 cleared colonization, n = 106 non-colonized any serotype) STV (n = 9 persistent colonization, 
n = 33 cleared colonization, n = 106 non-colonized any serotype). *p < 0.05, **p < 0.01, ****p < 0.0001. Table S1 in Supplementary Material outlines the numbers 
in each group by colonizing serotype.
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In line with our own observations, animal models of GBS ST 
Ib and III disease (21–23) demonstrate an association between 
increased SIgA in breastmilk and pup survival. There have 
been few studies of the effect of breastmilk antibody on infant 
colonization, but a small study of breastfed infants challenged 
postnatally with non-pathogenic E. coli demonstrated a reduc-
tion in colonization with high breastmilk SIgA concentrations 
(24), whilst studies of H. influenzae (25), S. pneumoniae (26), 
and N. meningitides (27) demonstrate that increasing antibody 
concentrations in serum are associated with reduced risk of 
pharyngeal colonization with these bacteria. If the same is true 
of SIgA in breastmilk and GBS colonization, then increasing 
maternally derived antibody in breastmilk in conjunction with 
increasing serum antibody through vaccination could interrupt 
GBS colonization and subsequently development of GBS disease.
The highest concentration of SIgA antibody in milk was 
found in mother/infant pairs where the mother but not the 
infant was colonized. This could be explained by the develop-
ment of an immune response in the mother, triggered by a new 
GBS challenge. This antibody is then passed to the infant and 
acts in a protective fashion. Timing of acquisition of maternal 
GBS colonization is likely to be important but our study was not 
able to assess this aspect. The fact that mother/infant pairs who 
remain completely non-colonized also have high concentrations 
of anti-GBS SIgA antibody indicates a long half-life of IgA during 
lactation due to previous colonization, as has been seen in moth-
ers vaccinated with N. meningitidis vaccines (28). Alternatively, 
this could also be due to another cross-reactive antigen that we 
have not identified.
Our finding of the association between TNFα and de novo 
GBS colonization fits with the results of the only other published 
study of breastmilk cytokines and infant disease by Riskin et al. 
(2012). This study analyzed the breastmilk of exclusively breast-
feeding mothers of 31 sick infants under 3  months of age and 
FigUre 2 | Comparison of cytokine concentrations in colostrum, breastmilk, cord blood, and infant serum. Box-and-whisker plot of concentrations of TNFα, IFN-γ, 
IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, and IL-13 in colostrum, breastmilk, cord, and infant serum in picograms per milliliter (pg/mL). 100 samples were assessed. 
Median and interquartile range is demonstrated. Solid shapes indicate outliers. *p = <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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demonstrated that increases in TNFα in colostrum were associ-
ated with acute infant disease, whether or not the mother was also 
sick (29). A possible explanation is that colostral TNFα induced 
an increase of MHC class II expression on antigen presenting 
cells (30) and expression of receptors that facilitate transcytosis 
of SIgA into exocrine fluids in the respiratory and gastrointestinal 
tracts to counteract infection (31). In vitro studies have similarly 
demonstrated that increased TNFα was associated with altered 
binding of E. coli in intestinal cells (32). If the same is true with 
GBS, then increased colostral TNFα could reduce GBS binding 
to neonatal gut epithelium and reduce the risk of systemic inva-
sion by inducing IgA at the mucosal surface.
Our observation that early infant colonization was associated 
with increased concentrations of IL-10 and TGF-β might be 
explained by IL-6-driven synthesis of IgM and IgG together with 
TGF-β as part of the maternal immune response to a pathogen 
during active infection, which equally increases IgA synthesis 
from naive B  cells (33). However, it is also possible that the 
cytokines in breastmilk result from local immune activation in 
the mammary glands due to GBS in breastmilk. These hypotheses 
remain speculative at present and future longitudinal studies of 
breastmilk and assessment of function of infant gut epithelial cells 
in response to pathogen challenge would be required to provide 
more insight into this phenomenon.
Our study has several limitations. As cytokines vary within 
and between mothers, our data can only provide a cross-sectional 
snapshot and a larger cohort with longitudinal maternal sampling 
is needed to fully appreciate the implications of these results. 
FigUre 3 | Cytokine concentrations in colostrum by infant group B Streptococcus (GBS) colonization status at day 6. Box-and-whisker plot of colostrum 
concentrations of TNFα, IL-6, IL-10, and log10 values of TGF-β1 in picograms per mililitre (pg/mL). 65 of the 100 samples had cytokine concentrations above the 
lower limit of detection. Geometric mean and 95% confidence interval is demonstrated. Solid shapes indicate outliers. *p = <0.05, **p < 0.01.
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On average 10 of the 100 samples analyzed for each cytokine had 
levels below the limit of detection of our assay and we have allo-
cated an arbitrary level of half the lower limit of detection into our 
results as the most robust way of dealing with these data. There 
is the possibility that this may introduce bias into our results but 
this is reduced by the analysis of logged data.
Additionally, the data surrounding the associations between 
acquisition and loss of infant GBS colonization do not take into 
account maternal colonization at each time point, as this was only 
measured in mothers at delivery. Maternal colonization is tran-
sient (34) and we cannot be certain that mothers who were not 
colonized at birth did not acquire GBS colonization themselves 
during the study. The collection of repeat rectovaginal swabs 
from the mothers in addition to breastmilk and infant samples 
was beyond the scope of our study. In future studies, it might 
be possible to consent for longitudinal swabbing in order to 
better understand the dynamics between maternal colonization, 
breastmilk SIgA, cytokine production and subsequent infant 
colonization over time.
We did not conduct any analysis of the association between 
cytokines and SIgA antibody and GBS colonization as the com-
plexity of the model and the sample size needed was outside of the 
scope of this study. However, we have demonstrated that infants 
who remained non-colonized received high concentrations of 
SIgA in colostrum and high functional antibody in cord blood 
and infant serum (17), suggesting a role for both systemic and 
mucosal antibody in preventing GBS colonization.
The low numbers of mother/infant pairs colonized with GBS 
STIa and III precluded detailed analysis of these GBS serotypes, 
which are important causes of infant disease in many countries 
and represent two of the serotypes being targeted by the current 
vaccine candidates. The serotype distribution in The Gambia 
is different from that in the USA and Europe, and highlights 
the need to understand GBS serotype prevalence in different 
regions (13).
The lack of standardized protocols available for the measure-
ment of specific SIgA in breastmilk remains a limitation not just 
of this study, but in general, restricting comparison with other 
studies. Going forward, it will be very important for the field 
that assay standardization is undertaken in order to demonstrate 
consistency in our predictions of antibody-mediated protection 
from colonization and disease between studies, particularly when 
assessing novel vaccines against GBS and their potential impact 
on breastmilk factors.
We did not seek to measure cellular or functional mucosal 
immunity as part of our cytokine analysis, therefore the data 
do not offer mechanistic insights into the role of cytokines in 
breastmilk and interactions at the mucosal surface.
FigUre 4 | Radar plot of cytokine concentration in colostrum by group B Streptococcus (GBS) colonization status by colonization status of infants. Radar plot of 
median cytokine concentration in colostrum in pg/mL from: blue = non-colonized, green = persistently colonized infants, red = infants who acquired colonization 
and purple = infants who cleared colonization between birth and day 60–89. TGF-β values are shown as log10 pg/mL values.
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Finally, we made the assumption that the reduction in 
colonization is due to breastmilk cytokine and SIgA antibody 
concentrations. It is probable that protection from colonization 
at the mucosal surface is more complicated and includes both innate 
and adaptive factors associated with breastmilk (35) or the infants’ 
developing microbiome (1). Measurement of the complexity of 
breastmilk immunity is extremely challenging, as there are few 
methods available and to assess these additional aspects requires 
sophisticated phenotyping of breast milk immune cells. However, 
samples have been stored for a comprehensive proteomic inter-
rogation of breastmilk components and further work is ongoing.
In conclusion, our data support the notion that the risk of GBS 
colonization in infants diminishes as naturally acquired SIgA 
antibody in breastmilk increases as part of the maternal immune 
response to GBS, and that the presence of key cytokines such as 
TNFα, IL10, and TGF-β might further contribute to protection. 
Our findings support the idea that increasing SIgA through 
vaccinating mothers in pregnancy against GBS could have the 
same effect, provided the antibody levels and function induced by 
vaccination are similar or greater than that of naturally acquired 
antibody.
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